Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Hopes for AIDS Vaccine Still Alive Despite Setbacks

The lesson from 2 failed trials: The science must be more vigorous, experts say

By E.J. Mundell
HealthDay Reporter


Related Encyclopedia
 border=
Abscess
Acne
Actinomycosis
Acute Myeloid Leukemia (Adult)
More...

Related Healthscout Videos
 border=
Weighted Belt for Autism?
Teaching Old Docs New Tricks
Lead in Soil.
Lead in Soil
More...

Related Animations
 border=
Dental Cavities
Erectile Dysfunction
Menopause
More...

Related Drug Information
 border=
Abilify
Adderal XR
Augmentin
Bactroban Cream
More...

Related News Articles
 border=
Children Aware of Racism
Focusing on School Could Prevent Teen Pregnancies
Report: Young Athletes Need Dual Screening for Heart Defects
Native Tongue Begins in the Womb
More...

MONDAY, Dec. 1 (HealthDay News) -- Nobody said HIV would give up without a fight.

As World AIDS Day arrives Dec. 1, scientists are taking a sobering look back at what went wrong in recent, high-profile failures of two human trials of candidate AIDS vaccines.

Text Continues Below



The consensus: A viable vaccine is still very possible, and with it comes the potential to wipe out HIV/AIDS. But the science behind any new candidate vaccine must be much stronger than it has been in the past before testing begins in humans.

"We are going to be better served to try and find out the basics of what the immune response is to HIV, what the limitations are, and how we can tweak or change that, or come up with something entirely new," said Rowena Johnston, vice president of research at the Foundation for AIDS Research (amFAR) in New York City. "And only then can we start to think about a product that could be taken into humans."

Just two potential HIV vaccines have made it so far to human clinical trials: VaxGen's AIDSVAX, tested in Thailand, until the trial was stopped in 2003; and Merck & Co.'s HIV vaccine, which was tested in North and South America, the Caribbean and Australia, until it proved a failure in 2007.

In the Merck case, the trial results have also been shadowed by speculations that the vaccine somehow tweaked some recipients' immune systems to make them slightly more vulnerable to HIV infection.

Some experts in the field now believe that both vaccines were rushed too soon into human trials. One big flaw: Primate trials matched the vaccine to the strain of HIV the monkey was exposed to. That's unlike "real world" human infections, where people may be randomly confronted with any number of strains, experts said.

"What you want to do is have evidence in primates that you can block completely, or nearly completely, a challenge with at least one, if not two or three challenges with heterologous [varied] strains of virus," said U.S. AIDS pioneer Dr. Robert Gallo, who is credited (along with French researcher Luc Montagnier) of pinpointing HIV as the cause of AIDS back in the early 1980s.

Page:  1 | 2 | 3 | Next >>

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 12/1/2008

Related Links
 border=
From Healthscout's partner site on diet & exercise, MyDietExercise.com
QUIZ: What's your ideal body weight?
QUIZ: Check your body mass index (BMI) online!
QUIZ: Rate your carbohydrate intake





SOURCES: Wayne Koff, Ph.D., senior vice president, research and development, International AIDS Vaccine Initiative, New York City; Robert Gallo, M.D., director, Institute of Human Virology, University of Maryland School of Medicine, Baltimore; Rowena Johnston, Ph.D., vice president, research, Foundation for AIDS Research (amFAR), New York City


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service   Site Map
Advertising Policy